An observational study in Classic Congenital Adrenal Hyperplasia and 21-Hydroxylase Deficiency, sponsored by University Hospital, Lille. Recruiting at 1 site in France. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-24.
Sponsored by University Hospital, Lille · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Adrenal Hyperplasia, Congenital with a site in France — 6 open to participants now, 8 under way, 4 of them phase 3. Adrenal Hyperplasia, Congenital · France.
Among the 21 studies in Adrenal Hyperplasia, Congenital with a site in France, this one is the 8th largest by planned enrollment of the 10 observational ones that give a count, is one of 4 that started in 2026, is one of 10 observational ones, and was the 21st registered.
101 studies on the registry are indexed under Adrenal Hyperplasia, Congenital; 28 are open to participants now.
Browse Adrenal Hyperplasia, Congenital studies →6 of the 21 studies in Adrenal Hyperplasia, Congenital with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+ · Women only
Crinetics Pharmaceuticals Inc. · Sites in France, United States, Argentina and 10 more countries
Ages 1–17
Crinetics Pharmaceuticals Inc. · Sites in France, United States, Argentina and 12 more countries
Ages 18–74
H. Lundbeck A/S · Sites in France, United States, Denmark and 6 more countries
Ages 18–70
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 6+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 20 Adrenal Hyperplasia, Congenital studies recruiting now, 10 (50%) set no upper age limit and 9 (45%) stop at 75 or younger; 7 take children under 18; none take healthy volunteers.
This study: 18 Years to 65 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 7
First in 2008; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 61 across 44 observational studies indexed under Adrenal Hyperplasia, Congenital.
Median enrollment 76 across the 11 interventional studies, 94 across the 10 observational. Of the 10 that completed or were terminated, 2 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 21 have an industry lead sponsor. The 10 most frequent:
University Hospital, Lille is the lead sponsor of 631 studies on the registry; 142 are open to participants now.
University Hospital, Lille has 1 study filed under Adrenal Hyperplasia, Congenital — fewer than ten, so there is no comparison to draw.
4 of the studies in Adrenal Hyperplasia, Congenital with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07144163Phase 3Crinetics Pharmaceuticals Inc.A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia | 2027-05 |
| NCT07781267University Hospital, LillePediatric Congenital Adrenal Hyperplasia Management: Regret and Long-term Outcomes | 2027-03-08 |
| NCT06900153Assistance Publique - Hôpitaux de ParisParenting and CAH - 21-hydroxylase Deficiency | 2027-03-16 |
| NCT07718230Assistance Publique - Hôpitaux de ParisEvaluation of Circadian Hormonal Balance: LC-MS/MS Measurement of Salivary and Serum Steroids in Patients With Congenital Adrenal Hyperplasia | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 21 studies in Adrenal Hyperplasia, Congenital with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is a chronic endocrine disorder, often diagnosed in the neonatal period. Severe forms may lead to genital virilization in afected girls and adrenal crises. Management includes lifelong hormone replacement therapy and, historically, early genital surgery, although recent guidelines recommend delaying non-urgent procedures to preserve patient autonomy.This study hypothesizes that pediatric management, particularly early surgical interventions, may influence long-term satisfaction and the expression of regret in adulthood. We will conduct an observational cross-sectional study including adult patients diagnosed with CAH during childhood. Data will be collected using standardized questionnaires assessing medical regret, quality of life, sexual function, and psychological outcomes, together with clinical characteristics and past medical and surgical history.The primary outcome is the prevalence of regret related to pediatric care. Secondary outcomes include quality of life, sexual satisfaction, psychological status, and adaptation of hormonal therapy from adolescence to adulthood. Patient-reported outcomes (regret, quality of life, sexual function, and psychological outcomes) will be assessed in female participants only, male participants will be included for the evaluation of hormonal treatment adaptation.
Patients with classic congenital adrenal hyperplasia (CAH) followed in the departments of gynecology, endocrinology, and pediatrics at Lille University Hospital, France.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Standardized questionnaires assessing regret related to pediatric management, quality of life, sexual function, and psychological outcomes.
Regret related to pediatric management
Regret related to pediatric management assessed by the Decision Regret Scale (DRS)
Time frame: At study inclusion (baseline)
Quality of life
Quality of life assessed by the WHOQOL-BREF questionnaire
Time frame: at study inclusion (baseline)
Sexual function
Sexual function assessed by the Arizona Sexual Experience Scale (ASEX)
Time frame: at study inclusion (baseline)
Symptoms of anxiety and depression
Symptoms of anxiety and depression assessed by the Hospital Anxiety and Depression Scale (HADS)
Time frame: at study inclusion
Adaptation of hormonal treatment from adolescence to adulthood
Adaptation of hormonal treatments from adolescence to adulthood, assessed from medical history
Time frame: at study inclusion (baseline)
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Mar 2027, 8 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Adrenal Hyperplasia, Congenital →